The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection

American Journal of Preventive Medicine

Volumn 50, Issue 3, 2016, Pages 419-426

  Allison, Robert D ^a   Hale, Steven A ^b,c   Harvey, Bart J ^d   Hudson, Toni Marie L ^c   Livingston, Catherine J ^e   Sherin, Kevin M ^b,c,f   Uduhiri, Kelechi A ^g   Niebuhr, David W ^h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

^c FLORIDA DEPARTMENT OF HEALTH   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g Providence Hospital Washington DC   (United States)

^h Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

AMERICAN COLLEGE OF PREVENTIVE MEDICINE; ARTICLE; BEHAVIOR MODIFICATION; DRUG USE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL SOCIETY; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; OPIATE ADDICTION; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PRESCRIPTION; SCREENING TEST; MASS SCREENING; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; STANDARDS; UNITED STATES;

HEPATITIS C; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84958268023     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2015.12.001     Document Type: Article

References (66)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 4 2013 1333 1342 10.1002/hep.26141
2. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 12 2011 1118 1127 10.1056/NEJMra1001683
3. R.M. Klevens, S. Liu, H. Roberts, R.B. Jiles, and S.D. Holmberg Estimating acute viral hepatitis infections from nationally reported cases Am J Public Health 104 3 2014 482 487 10.2105/AJPH.2013.301601
4. M.M. Denniston, R.B. Jiles, J. Drobeniuc, and et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 Ann Intern Med 160 5 2014 293 300 10.7326/M13-1133
5. B.R. Edlin, B.J. Eckhardt, M.A. Shu, S.D. Holmberg, and T. Swan Toward a more accurate estimate of the prevalence of hepatitis C in the United States Hepatology 62 5 2015 1353 1363 10.1002/hep.27978
6. R.G. Gish, C.A. Cohen, J.M. Block, and et al. Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States Hepatology 62 5 2015 1339 1341 10.1002/hep.28026
7. R.D. Allison, C. Conry-Cantilena, D. Koziol, and et al. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors J Infect Dis 206 5 2012 654 661 10.1093/infdis/jis410
8. D.L. Thomas, C.L. Thio, M.P. Martin, and et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 798 801 10.1038/nature08463
9. H.K. Dyal, M. Aguilar, T. Bhuket, and et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among hcv patients: a systematic review Dig Dis Sci 60 9 2015 2813 2824 10.1007/s10620-015-3760-3
10. M.A. Konerman, S.H. Mehta, C.G. Sutcliffe, and et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs Hepatology 59 3 2014 767 775 10.1002/hep.26741
11. M. Stepanova, F. Kanwal, H.B. El-Serag, and Z.M. Younossi Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States Hepatology 53 3 2011 737 745 10.1002/hep.24131
12. Steele CB, Meléndez-Morales L, Campoluci R, DeLuca N, Dean HD. Health disparities in HIV/AIDS, viral hepatitis, sexually transmitted diseases, and tuberculosis: issues, burden, and response, a retrospective review, 2000-2004. Atlanta, GA: CDC, www.cdc.gov/nchhstp/healthdisparities/docs/nchhstphealthdisparitiesreport1107.pdf. Published 2007. Accessed October 17, 2015.
13. CDC Notes from the field: risk factors for hepatitis C virus infections among young adults-Massachusetts, 2010 MMWR Morb Mortal Wkly Rep 60 42 2011 1457 1458 www.cdc.gov/mmwr/pdf/wk/mm6042.pdf Accessed October 17, 2015
14. CDC Notes from the field: hepatitis C virus infections among young adults - rural Wisconsin, 2010 MMWR Morb Mortal Wkly Rep 61 19 2012 358 www.cdc.gov/mmwr/pdf/wk/mm6119.pdf Accessed October 17, 2015
15. A.G. Suryaprasad, J.Z. White, F. Xu, and et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012 Clin Infect Dis 59 10 2014 1411 1419 10.1093/cid/ciu643
16. J.E. Zibbell, K. Iqbal, R.C. Patel, and et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012 MMWR Morb Mortal Wkly Rep 64 17 2015 453 458
17. Viral hepatitis-Statistics & Surveillance. Surveillance for viral hepatitis-United States, 2013. CDC website. www.cdc.gov/hepatitis/statistics/2013surveillance/index.htm. Updated June 25, 2015. Accessed October 19, 2015.
18. Hepatitis C: testing baby boomers saves lives. CDC website. www.cdc.gov/features/vitalsigns/hepatitisc/. Updated May 2013. Accessed June 1, 2015.
19. V.A. Moyer Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 159 5 2013 349 357
20. R. Chou, E.B. Cottrell, N. Wasson, B. Rahman, and J.M. Guise Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 158 2 2013 101 108 10.7326/0003-4819-158-2-201301150-00574
21. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. Mcquillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 10 2006 705 714 10.7326/0003-4819-144-10-200605160-00004
22. R.A. Pollini, C.J. Banta-Green, J. Cuevas-Mota, M. Metzner, E. Teshale, and R.S. Garfein Problematic use of prescription-type opioids prior to heroin use among young heroin injectors Subst Abuse Rehabil 2 1 2011 173 180 10.2147/SAR.S24800
23. S.E. McCabe, J.A. Cranford, and B.T. West Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys Addict Behav 33 10 2008 1297 1305 10.1016/j.addbeh.2008.06.005
24. P. Vickerman, N.K. Martin, and M. Hickman Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings - implications for intervention impact Drug Alcohol Depend 123 1-3 2012 122 131 10.1016/j.drugalcdep.2011.10.032
25. S. Yaphe, N. Bozinoff, R. Kyle, S. Shivkumar, N.P. Pai, and M. Klein Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review Sex Transm Infect 88 7 2012 558 564 10.1136/sextrans-2012-050566
26. C. Beyrer, S.D. Baral, F. Van Griensven, and et al. Global epidemiology of HIV infection in men who have sex with men Lancet 380 9839 2012 367 377 10.1016/S0140-6736(12)60821-6
27. D. Bradshaw, G. Matthews, and M. Danta Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 26 1 2013 66 72 10.1097/QCO.0b013e32835c2120
28. M.D. Witt, E.C. Seaberg, A. Darilay, and et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011 Clin Infect Dis 57 1 2013 77 84 10.1093/cid/cit197
29. S.P. Buchbinder, M.H. Katz, N.A. Hessol, J. Liu, P.M. O'malley, and M.J. Alter Hepatitis C virus infection in sexually active homosexual men J Infect 29 3 1994 263 269 10.1016/S0163-4453(94)91128-2
30. A.J. Schmidt, J.K. Rockstroh, M. Vogel, and et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany - a case-control study PLoS ONE 6 3 2011 e17781 10.1371/journal.pone.0017781
31. G. Colfax, E. Vittinghoff, M.J. Husnik, and et al. Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men Am J Epidemiol 159 10 2004 1002 1012 10.1093/aje/kwh135
32. A.T. Urbanus, T.J. Van de laar, I.G. Stolte, and et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic AIDS 23 12 2009 F1 F7 10.1097/QAD.0b013e32832e5631
33. S.D. Holmberg, P.R. Spradling, A.C. Moorman, and M.M. Denniston Hepatitis C in the United States N Engl J Med 368 20 2013 1859 1861 10.1056/NEJMp1302973
34. J.W. Galbraith Hepatitis C virus screening: an important public health opportunity for United States emergency departments Ann Emerg Med 2015 10.1016/j.annemergmed.2015.08.002
35. B.J. Turner, B.S. Taylor, J. Hanson, and et al. High priority for hepatitis C screening in safety net hospitals: results from a prospective cohort of 4582 hospitalized baby boomers Hepatology 62 5 2015 1388 1395 10.1002/hep.28018
36. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org. Accessed October 19, 2015.
37. Hepatitis C community. University of New Mexico School of Medicine. Project ECHO website. echo.unm.edu/nm-teleecho-clinics/hepatitis-c-community-clinic/. Accessed June 1, 2015.
38. E. Everhart Viral hepatitis J.E. Everhart, The Burden of Digestive Diseases in the United States. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2008 U.S. Government Printing Office Washington, DC 13 23
39. A.C. El Khoury, W.K. Klimack, C. Wallace, and H. Razavi Economic burden of hepatitis C-associated diseases in the United States J Viral Hepat 19 3 2012 153 160 10.1111/j.1365-2893.2011.01563.x
40. R.P. Myers, M. Krajden, M. Bilodeau, and et al. Burden of disease and cost of chronic hepatitis C infection in Canada Can J Gastroenterol Hepatol 28 5 2014 243 250
41. M.S. Saag Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL Clin Infect Dis 61 2 2015 169 170 10.1093/cid/civ221
42. S. Barua, R. Greenwald, J. Grebely, G.J. Dore, T. Swan, and L.E. Taylor Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States Ann Intern Med 163 3 2015 215 223 10.7326/M15-0406
43. L.A. Canary, R.M. Klevens, and S.D. Holmberg Limited access to new hepatitis C virus treatment under state Medicaid programs Ann Intern Med 163 3 2015 226 228 10.7326/M15-0320
44. American Association for the Study of Liver Diseases/Infectious Disease Society of America/International Antiviral Society-USA. Overview of cost, reimbursement, and cost-effectiveness considerations for hepatitis C treatment regimens. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment. Accessed October 19, 2015.
45. M. Imran, S. Manzoor, N.M. Khattak, and et al. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets Arch Virol 159 5 2014 831 846 10.1007/s00705-013-1803-7
46. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N Engl J Med 368 20 2013 1907 1917 10.1056/NEJMra1213651
47. American Association for the Study of Liver Diseases/Infectious Disease Society of America/International Antiviral Society-USA. Initial treatment of HCV infection. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment. Accessed October 19, 2015.
48. J. Chhatwal, F. Kanwal, M.S. Roberts, and M.A. Dunn Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States Ann Intern Med 162 6 2015 397 406 10.7326/M14-1336
49. A.J. Leidner, H.W. Chesson, F. Xu, J.W. Ward, P.R. Spradling, and S.D. Holmberg Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease Hepatology 61 6 2015 1860 1869 10.1002/hep.27736
50. B.P. Linas, D.M. Barter, J.R. Morgan, and et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection Ann Intern Med 162 9 2015 619 629 10.7326/M14-1313
51. M. Najafzadeh, K. Andersson, W.H. Shrank, and et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus Ann Intern Med 162 6 2015 407 419 10.7326/M14-1152
52. D.B. Rein, J.S. Wittenborn, B.D. Smith, D.K. Liffmann, and J.W. Ward The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus Clin Infect Dis 61 2 2015 157 168 10.1093/cid/civ220
53. Z.M. Younossi, H. Park, S. Saab, A. Ahmed, D. Dieterich, and S.C. Gordon Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection Aliment Pharmacol Ther 41 6 2015 544 563 10.1111/apt.13081
54. C. Jézeéquel, E. Bardou-Jacquet, Y. Desille, and et al. Survival of patients infected by chronic hepatitis C and f0f1 fibrosis at baseline after a 15 years follow-up J Hepatol 62 suppl 2 2015 589
55. Zahnd C, Salazar-Vizcaya LP, Dufour JF. et al. Impact of deferring HCV treatment on liver-related events in HIV+ patients. Conference on Retroviruses and Opportunistic Infections (CROI) 2015, Seattle, WA, February 23-26, 2015. Abstract no. 150.
56. American Liver Foundation. Hepatitis diagnosis, treatment and support. hepc.liverfoundation.org/diagnosis/who-should-get-tested/. Accessed June 1, 2015.
57. H.M. Colvin, and A.E. Mitchell Committee on the Prevention and Control of Viral Hepatitis Infections; IOM. Hepatitis and Liver Cancer: A National Strategy for the Prevention and Control of Viral Hepatitis Infections 2010 National Academies Press Washington, DC
58. Canadian Liver Foundation. Hepatitis C. www.liver.ca/liver-disease/types/viral-hepatitis/Hepatitis-C.aspx#2. Accessed June 1, 2015.
59. The Joint Commission. Performance measurement for hospitals. Facts about ORYX® for hospitals (National Hospital Quality Measures). www.jointcommission.org/accreditation/performance-measurementoryx.aspx. Accessed October 17, 2015.
60. National Center for Quality Assurance. HEDIS & performance measurement. www.ncqa.org/HEDISQualityMeasurement.aspx. Accessed October 17, 2015.
61. Center for Medicare and Medicaid Services. Physician Quality Reporting System. www.ncqa.org/HEDISQualityMeasurement.aspx. Accessed October 17, 2015.
62. S.C. Williams, S.P. Schmaltz, D.J. Morton, R.G. Koss, and J.M. Loeb Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004 N Engl J Med 353 3 2005 255 264 10.1056/NEJMsa043778
63. R.M. Werner, and E.T. Bradlow Relationship between Medicare's hospital compare performance measures and mortality rates JAMA 296 22 2006 2694 2702 10.1001/jama.296.22.2694
64. E.D. Peterson, M.T. Roe, J. Mulgund, and et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes JAMA 295 16 2006 1912 1920 10.1001/jama.295.16.1912
65. American Gastroenterological Association. The Physician Quality Reporting System (PQRS) and value-based payment modifier. North Chicago, IL. www.gastro.org/practice-management/quality/400-1683302-PQRS-and-VBM-for-HCV-Flashcard.pdf. Published May 2015. Accessed June 1, 2015.
66. Office of HIV/AIDS and Infectious Disease Policy. Action plan for prevention, care and treatment of viral hepatitis. Washington, DC. www.aids.gov/pdf/viral-hepatitis-action-plan.pdf. Accessed June 1, 2015.